H2 receptor antagonists probably leads to lower number of participants requiring blood transfusions compared with placebo or no prophylaxis (moderate certainty).
The review found no eligible studies for this question.
H2 receptor antagonists may leads to higher clinically important upper GI bleeding compared with proton pump inhibitors (low certainty).
H2 receptor antagonists showed no clear difference in nosocomial pneumonia compared with proton pump inhibitors (low certainty).
H2 receptor antagonists showed no clear difference in all‐cause mortality in ICU compared with proton pump inhibitors (low certainty).
H2 receptor antagonists showed no clear difference in number of participants requiring blood transfusion compared with proton pump inhibitors (moderate certainty).
The review found no eligible studies for this question.
H2 receptor antagonists showed no clear difference in clinically important upper GI bleeding compared with antacids (low certainty).
H2 receptor antagonists showed no clear difference in nosocomial pneumonia compared with antacids (low certainty).
It is very uncertain whether H2 receptor antagonists changes all‐cause mortality in ICU compared with antacids (very low certainty).
The review found no eligible studies for this question.
H2 receptor antagonists probably leads to higher number of participants requiring blood transfusion compared with antacids (moderate certainty).
The review found no eligible studies for this question.
H2 receptor antagonists showed no clear difference in clinically important upper GI bleeding compared with sucralfate (low certainty).
H2 receptor antagonists probably leads to higher nosocomial pneumonia compared with sucralfate (moderate certainty).
H2 receptor antagonists showed no clear difference in all‐cause mortality in ICU compared with sucralfate (low certainty).
H2 receptor antagonists showed no clear difference in number of participants requiring blood transfusion compared with sucralfate (low certainty).